Technical Analysis for ABUS - Arbutus Biopharma Corporation
|Grade||Last Price||% Change||$ Change|
ABUS closed up 1.56 percent on Monday, March 27, 2017, on 63 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Trend Table & Recent Alerts
|See historical ABUS trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 27||Upside 200 DMA Break||Bullish||0.00%|
|Mar 27||Calm After Storm||Range Contraction||0.00%|
|Mar 24||200 DMA Resistance||Bearish||1.56%|
|Mar 24||Calm After Storm||Range Contraction||1.56%|
|Mar 23||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||3.17%|
|Mar 23||Calm After Storm||Range Contraction||3.17%|
|Mar 22||Upper Bollinger Band Walk||Other||3.17%|
|Mar 22||Calm After Storm||Range Contraction||3.17%|
|Mar 21||Downside 200 DMA Break||Bearish||1.56%|
|Mar 21||Wide Range Bar||Range Expansion||1.56%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The companys products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ABUS news...
|52 Week High||5.48|
|52 Week Low||2.35|
|200-Day Moving Average||3.2132|
|50-Day Moving Average||2.7382|
|20-Day Moving Average||2.899|
|10-Day Moving Average||3.105|
|Average True Range||0.1686|
|Chandelier Exit (Long, 3 ATRs)||2.9842|
|Chandelier Exit (Short, 3 ATRs)||3.0558|
|Upper Bollinger Band||3.4221|
|Lower Bollinger Band||2.3759|
|Percent B (%b)||0.84|